$REGN
REGENERON PHARMACEUTICALS, INC. Stock $regn

$regn Overview Financials Valuation SEC Filings Company Website

2017 Q4 Form 10-K Financial Statement

#000153217619000009 Filed on February 07, 2019

Income Statement

Concept	2017 Q4	2017 Q3	2017 Q2
Revenue	$1.582B	$1.501B	$1.470B
YoY Change	28.99%	22.99%	21.23%
Cost Of Revenue	$105.7M	$46.39M	$42.13M
YoY Change	41.5%	55.14%	2.15%
Gross Profit	$1.477B	$1.454B	$1.428B
YoY Change	28.17%	22.19%	21.91%
Gross Profit Margin	93.32%	96.91%	97.13%
Selling, General & Admin	$409.9M	$306.8M	$306.9M
YoY Change	25.77%	13.6%	5.09%
% of Gross Profit	27.76%	21.09%	21.49%
Research & Development	$528.0M	$529.7M	$510.0M
YoY Change	10.18%	-2.45%	-8.92%
% of Gross Profit	35.76%	36.43%	35.71%
Depreciation & Amortization	$34.50M	$37.80M	$35.10M
YoY Change	19.38%	35.97%	40.4%
% of Gross Profit	2.34%	2.6%	2.46%
Operating Expenses	$937.9M	$836.5M	$816.9M
YoY Change	16.49%	2.88%	-4.12%
Operating Profit	$538.8M	$559.9M	$550.3M
YoY Change	55.27%	54.33%	88.7%
Interest Expense	-$6.000M	$6.182M	$5.401M
YoY Change	76.47%	-1346.37%	-531.73%
% of Operating Profit	-1.11%	1.1%	0.98%
Other Income/Expense, Net	$22.00M	$5.679M	-$24.46M
YoY Change	-1147.62%	84.44%	-3995.22%
Pretax Income	$554.8M	$565.6M	$525.9M
YoY Change	62.46%	54.59%	79.93%
Income Tax	$55.00M	$177.3M	$138.1M
% Of Pretax Income	9.91%	31.34%	26.26%
Net Earnings	$173.5M	$388.3M	$387.7M
YoY Change	-31.45%	46.64%	97.59%
Net Earnings / Revenue	10.96%	25.88%	26.37%
Basic Earnings Per Share	$1.62	$3.64	$3.66
Diluted Earnings Per Share	$1.50	$3.32	$3.34
COMMON SHARES
Basic Shares Outstanding		106.7M shares	106.0M shares
Diluted Shares Outstanding		117.0M shares	116.1M shares

Balance Sheet

Concept	2017 Q4	2017 Q3	2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.410B	$1.379B	$1.268B
YoY Change	35.71%	-2.06%	21.34%
Cash & Equivalents	$812.7M	$792.1M	$744.3M
Short-Term Investments	$597.0M	$587.0M	$524.0M
Other Short-Term Assets	$437.0M	$357.0M	$381.0M
YoY Change	96.85%	99.44%	141.14%
Inventory	$726.1M	$641.6M	$554.3M
Prepaid Expenses
Receivables	$1.539B	$1.533B	$1.420B
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$4.335B	$4.136B	$3.860B
YoY Change	36.31%	18.11%	20.28%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.359B	$2.275B	$2.262B
YoY Change	13.21%	21.49%	27.57%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$1.486B	$1.327B	$1.065B
YoY Change	71.99%	70.57%	80.51%
Other Assets	$77.90M	$36.62M	$36.96M
YoY Change	283.86%	76.86%	450.45%
Total Long-Term Assets	$4.429B	$4.565B	$4.246B
YoY Change	16.77%	37.25%	41.75%
TOTAL ASSETS
Total Short-Term Assets	$4.335B	$4.136B	$3.860B
Total Long-Term Assets	$4.429B	$4.565B	$4.246B
Total Assets	$8.764B	$8.701B	$8.106B
YoY Change	25.68%	27.43%	30.64%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$178.2M	$154.0M	$151.0M
YoY Change	32.0%	24.19%	48.04%
Accrued Expenses	$637.0M	$538.0M	$542.0M
YoY Change	25.39%	23.68%	11.07%
Deferred Revenue	$320.1M
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$0.00	$0.00
YoY Change	-100.0%
Total Short-Term Liabilities	$1.136B	$1.139B	$1.029B
YoY Change	-8.54%	18.46%	8.14%
LONG-TERM LIABILITIES
Long-Term Debt	$703.0M	$702.0M	$701.0M
YoY Change	99.72%	83.77%	93.65%
Other Long-Term Liabilities	$152.0M	$125.2M	$115.9M
YoY Change	51.42%	-7.72%	-3.01%
Total Long-Term Liabilities	$152.0M	$125.2M	$115.9M
YoY Change	51.42%	-7.72%	-3.01%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.136B	$1.139B	$1.029B
Total Long-Term Liabilities	$152.0M	$125.2M	$115.9M
Total Liabilities	$2.620B	$2.650B	$2.586B
YoY Change	3.8%	13.39%	21.48%
SHAREHOLDERS EQUITY
Retained Earnings	$2.947B	$2.773B	$2.385B
YoY Change	68.55%	85.49%	93.85%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)	$316.2M	$316.2M	$316.2M
YoY Change	-0.01%	0.06%	0.06%
Treasury Stock Shares	3.764M shares	3.764M shares	3.764M shares
Shareholders Equity	$6.144B	$6.052B	$5.521B
YoY Change
Total Liabilities & Shareholders Equity	$8.764B	$8.701B	$8.106B
YoY Change	25.68%	27.43%	30.64%

Cashflow Statement

Concept	2017 Q4	2017 Q3	2017 Q2
OPERATING ACTIVITIES
Net Income	$173.5M	$388.3M	$387.7M
YoY Change	-31.45%	46.64%	97.59%
Depreciation, Depletion And Amortization	$34.50M	$37.80M	$35.10M
YoY Change	19.38%	35.97%	40.4%
Cash From Operating Activities	$566.9M	$414.9M	-$30.60M
YoY Change	45.21%	-36.27%	-107.66%
INVESTING ACTIVITIES
Capital Expenditures	-$107.6M	-$59.70M	-$54.80M
YoY Change	-28.46%	-49.66%	-60.52%
Acquisitions
YoY Change
Other Investing Activities	-$228.1M	-$299.3M	-$115.5M
YoY Change	88.82%	4.18%	-38.3%
Cash From Investing Activities	-$335.8M	-$358.8M	-$170.5M
YoY Change	23.77%	-11.58%	-47.7%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-210.5M	-8.200M	133.5M
YoY Change	-57.2%	-128.57%	-527.88%
NET CHANGE
Cash From Operating Activities	566.9M	414.9M	-30.60M
Cash From Investing Activities	-335.8M	-358.8M	-170.5M
Cash From Financing Activities	-210.5M	-8.200M	133.5M
Net Change In Cash	20.60M	47.90M	-67.60M
YoY Change	-105.53%	-82.51%	-259.81%
FREE CASH FLOW
Cash From Operating Activities	$566.9M	$414.9M	-$30.60M
Capital Expenditures	-$107.6M	-$59.70M	-$54.80M
Free Cash Flow	$674.5M	$474.6M	$24.20M
YoY Change	24.72%	-38.33%	-95.5%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2018	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2018	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
CY2018	dei	Amendment Flag AmendmentFlag	false
CY2018	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2018	dei	Document Period End Date DocumentPeriodEndDate	2018-12-31
CY2018	dei	Document Type DocumentType	10-K
CY2018	dei	Entity Central Index Key EntityCentralIndexKey	0000872589
CY2018	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2018	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2018	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2018Q2	dei	Entity Public Float EntityPublicFloat	35741000000	USD
CY2018	dei	Entity Registrant Name EntityRegistrantName	REGENERON PHARMACEUTICALS INC
CY2018	dei	Entity Shell Company EntityShellCompany	false
CY2018	dei	Entity Small Business EntitySmallBusiness	false
CY2018	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2018	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2016Q4	regn	Accrued Capital Expenditures AccruedCapitalExpenditures	28200000	USD
CY2017Q4	regn	Accrued Capital Expenditures AccruedCapitalExpenditures	41800000	USD
CY2018Q4	regn	Accrued Capital Expenditures AccruedCapitalExpenditures	54500000	USD
CY2017Q4	regn	Accrued Clinical Trial Expense Current AccruedClinicalTrialExpenseCurrent	120900000	USD
CY2018Q4	regn	Accrued Clinical Trial Expense Current AccruedClinicalTrialExpenseCurrent	142200000	USD
CY2017Q4	regn	Accruedsalesrelatedchargesdeductionsandroyalties Accruedsalesrelatedchargesdeductionsandroyalties	194500000	USD
CY2018Q4	regn	Accruedsalesrelatedchargesdeductionsandroyalties Accruedsalesrelatedchargesdeductionsandroyalties	182700000	USD
CY2017Q4	regn	Accumulated Amortization Of Capital And Facility Leases AccumulatedAmortizationOfCapitalAndFacilityLeases	47900000	USD
CY2018Q4	regn	Accumulated Amortization Of Capital And Facility Leases AccumulatedAmortizationOfCapitalAndFacilityLeases	61700000	USD
CY2017Q1	regn	Aggregatefundingadvancedbytheparticipants Aggregatefundingadvancedbytheparticipants	720000000	USD
CY2017Q4	regn	Capital And Facility Leases At Cost CapitalAndFacilityLeasesAtCost	724100000	USD
CY2018Q4	regn	Capital And Facility Leases At Cost CapitalAndFacilityLeasesAtCost	723900000	USD
CY2017Q4	regn	Capitalandfacilityleaseobligationsnoncurrent Capitalandfacilityleaseobligationsnoncurrent	703500000	USD
CY2018Q4	regn	Capitalandfacilityleaseobligationsnoncurrent Capitalandfacilityleaseobligationsnoncurrent	708500000	USD
CY2016	regn	Depreciation Depletion And Amortization Excluding Intangible Assets DepreciationDepletionAndAmortizationExcludingIntangibleAssets	104700000	USD
CY2017	regn	Depreciation Depletion And Amortization Excluding Intangible Assets DepreciationDepletionAndAmortizationExcludingIntangibleAssets	142200000	USD
CY2018	regn	Depreciation Depletion And Amortization Excluding Intangible Assets DepreciationDepletionAndAmortizationExcludingIntangibleAssets	144100000	USD
CY2016	regn	Effective Income Tax Rate Reconciliation Deduction Foreign Intangible Income Percent EffectiveIncomeTaxRateReconciliationDeductionForeignIntangibleIncomePercent	0.000
CY2017	regn	Effective Income Tax Rate Reconciliation Deduction Foreign Intangible Income Percent EffectiveIncomeTaxRateReconciliationDeductionForeignIntangibleIncomePercent	0.000
CY2018	regn	Effective Income Tax Rate Reconciliation Deduction Foreign Intangible Income Percent EffectiveIncomeTaxRateReconciliationDeductionForeignIntangibleIncomePercent	0.010
CY2016	regn	Effective Income Tax Rate Reconciliation Sale Of Non Inventory Related Assets Between Foreign Subsidiaries Percent EffectiveIncomeTaxRateReconciliationSaleOfNonInventoryRelatedAssetsBetweenForeignSubsidiariesPercent	0.000
CY2017	regn	Effective Income Tax Rate Reconciliation Sale Of Non Inventory Related Assets Between Foreign Subsidiaries Percent EffectiveIncomeTaxRateReconciliationSaleOfNonInventoryRelatedAssetsBetweenForeignSubsidiariesPercent	0.000
CY2018	regn	Effective Income Tax Rate Reconciliation Sale Of Non Inventory Related Assets Between Foreign Subsidiaries Percent EffectiveIncomeTaxRateReconciliationSaleOfNonInventoryRelatedAssetsBetweenForeignSubsidiariesPercent	-0.063
CY2016Q4	regn	Facility Purchase Price FacilityPurchasePrice	720000000	USD
CY2017Q1	regn	Initialtermoflease Initialtermoflease	P5Y
CY2018Q4	regn	Maximumsharesthecollaboratorcouldsell Maximumsharesthecollaboratorcouldsell	1173847	shares
CY2018Q1	regn	Maximumsharesthecollaboratorcouldsell Maximumsharesthecollaboratorcouldsell	1400000	shares
CY2018	regn	Number Of Demand Rights To Require The Company To Conduct Registered Underwritten Public Offering NumberOfDemandRightsToRequireTheCompanyToConductRegisteredUnderwrittenPublicOffering	3	demand_right
CY2017Q4	regn	Paymenttowardspurchasepriceof Tarrytownfacility PaymenttowardspurchasepriceofTarrytownfacility	57000000	USD
CY2017Q1	regn	Potentialextendedtermoflease Potentialextendedtermoflease	P5Y
CY2017Q1	regn	Reimbursementreceivedbythe Company ReimbursementreceivedbytheCompany	57000000	USD
CY2017Q4	regn	Tarrytownfacilitycapitalandfacilityleaseobligations Tarrytownfacilitycapitalandfacilityleaseobligations	720000000	USD
CY2017Q4	regn	Tax Cuts And Jobs Act Of2017 Incomplete Accounting Provisional Income Tax Expense Benefit TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit	326200000	USD
CY2017Q4	regn	Tax Cutsand Jobs Actof2017 Incomplete Accounting Changein Tax Rate Provisional Income Tax Expense Benefit TaxCutsandJobsActof2017IncompleteAccountingChangeinTaxRateProvisionalIncomeTaxExpenseBenefit	326200000	USD
CY2018	regn	Tax Cutsand Jobs Actof2017 Measurement Period Adjustment Income Tax Expense Benefit TaxCutsandJobsActof2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit	-68000000	USD
CY2016	regn	Unrecognized Tax Benefits Decrease Resulting From Settlements With Taxing Authorities And Reduction Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsDecreaseResultingFromSettlementsWithTaxingAuthoritiesAndReductionResultingFromLapseOfApplicableStatuteOfLimitations	2700000	USD
CY2017	regn	Unrecognized Tax Benefits Decrease Resulting From Settlements With Taxing Authorities And Reduction Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsDecreaseResultingFromSettlementsWithTaxingAuthoritiesAndReductionResultingFromLapseOfApplicableStatuteOfLimitations	14400000	USD
CY2018	regn	Unrecognized Tax Benefits Decrease Resulting From Settlements With Taxing Authorities And Reduction Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsDecreaseResultingFromSettlementsWithTaxingAuthoritiesAndReductionResultingFromLapseOfApplicableStatuteOfLimitations	13700000	USD
CY2017Q4	us-gaap	Accounts And Notes Receivable Net AccountsAndNotesReceivableNet	242000000	USD
CY2018Q4	us-gaap	Accounts And Notes Receivable Net AccountsAndNotesReceivableNet	293100000	USD
CY2017Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	637200000	USD
CY2018Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	772100000	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	178200000	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	218200000	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1538600000	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1723700000	USD
CY2017Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	193700000	USD
CY2018Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	226400000	USD
CY2017Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	637200000	USD
CY2018Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	772100000	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	566300000	USD
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	728700000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	600000	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-12300000	USD
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3512900000	USD
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3911600000	USD
CY2016	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	143200000	USD
CY2017	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	301700000	USD
CY2018	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	187200000	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments	47800000	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	-643300000	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	574900000	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	524600000	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	444800000	USD
CY2016	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	590400000	USD
CY2017	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	108600000	USD
CY2018	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	-249300000	USD
CY2017Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2018Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2017Q4	us-gaap	Assets Assets	8764300000	USD
CY2018Q4	us-gaap	Assets Assets	11734500000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	4335000000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	6447600000	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	2200000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1000000	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	8900000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	18400000	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	2027300000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	3026600000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	1426800000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	1667000000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	593800000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	1342200000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	2020600000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	3009200000	USD
CY2016	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	154900000	USD
CY2017	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	201200000	USD
CY2018Q4	us-gaap	Capital Leases Future Minimum Payments Due CapitalLeasesFutureMinimumPaymentsDue	89700000	USD
CY2018Q4	us-gaap	Capital Leases Future Minimum Payments Due Current CapitalLeasesFutureMinimumPaymentsDueCurrent	26400000	USD
CY2018Q4	us-gaap	Capital Leases Future Minimum Payments Due In Five Years CapitalLeasesFutureMinimumPaymentsDueInFiveYears	0	USD
CY2018Q4	us-gaap	Capital Leases Future Minimum Payments Due In Four Years CapitalLeasesFutureMinimumPaymentsDueInFourYears	7000000	USD
CY2018Q4	us-gaap	Capital Leases Future Minimum Payments Due In Three Years CapitalLeasesFutureMinimumPaymentsDueInThreeYears	27900000	USD
CY2018Q4	us-gaap	Capital Leases Future Minimum Payments Due In Two Years CapitalLeasesFutureMinimumPaymentsDueInTwoYears	28400000	USD
CY2018Q4	us-gaap	Capital Leases Future Minimum Payments Due Thereafter CapitalLeasesFutureMinimumPaymentsDueThereafter	0	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	535200000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	812700000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1467700000	USD
CY2016	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-261400000	USD
CY2017	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	277500000	USD
CY2018	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	655000000	USD
CY2015Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	809100000	USD
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	547700000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	825200000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1480200000	USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	874100000	USD
CY2017	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	1212000000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	2438100000	USD
CY2017Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	320100000	USD
CY2018Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	452500000	USD
CY2017Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	629200000	USD
CY2018Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	464200000	USD
CY2016	us-gaap	Costs And Expenses CostsAndExpenses	3529700000	USD
CY2017	us-gaap	Costs And Expenses CostsAndExpenses	3792600000	USD
CY2018	us-gaap	Costs And Expenses CostsAndExpenses	4176400000	USD
CY2016	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	787000000	USD
CY2017	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	560300000	USD
CY2018	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	223700000	USD
CY2016	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	-1400000	USD
CY2017	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	4800000	USD
CY2018	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	20600000	USD
CY2016	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	794400000	USD
CY2017	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	561000000	USD
CY2018	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	249100000	USD
CY2016	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	8800000	USD
CY2017	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-4100000	USD
CY2018	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	4800000	USD
CY2017Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	324700000	USD
CY2018Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	900700000	USD
CY2017Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	3600000	USD
CY2018Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	12300000	USD
CY2017Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	1041500000	USD
CY2018Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	1482600000	USD
CY2017Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	5300000	USD
CY2018Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	6100000	USD
CY2017Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	1366200000	USD
CY2018Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	2383300000	USD
CY2017Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	8900000	USD
CY2018Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	18400000	USD
CY2016	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-377400000	USD
CY2017	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	317100000	USD
CY2018	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	687600000	USD
CY2016	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	3900000	USD
CY2017	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	3200000	USD
CY2018	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-825700000	USD
CY2017Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	506300000	USD
CY2018Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	828700000	USD
CY2016	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-360100000	USD
CY2017	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	319000000	USD
CY2018	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-140000000	USD
CY2017Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	47700000	USD
CY2018Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	2700000	USD
CY2016	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	13400000	USD
CY2017	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-1300000	USD
CY2018	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-1900000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	102400000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	20200000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	558200000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	672800000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	506300000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	670100000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	554000000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	672800000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	26500000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	33300000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	0	USD
CY2018Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	107800000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	391000000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	458200000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	38300000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	53300000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	4200000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	0	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	3100000	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	2700000	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	44600000	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	0	USD
CY2016	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	17700000	USD
CY2017	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	19600000	USD
CY2018	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	27000000	USD
CY2016	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	104700000	USD
CY2017	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	145500000	USD
CY2018	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	148200000	USD
CY2016	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	8.55
CY2017Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.36
CY2017Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.66
CY2017Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.64
CY2017Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.62
CY2017	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	11.27
CY2018Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	4.44
CY2018Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	5.12
CY2018Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	5.50
CY2018Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	7.58
CY2018	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	22.65
CY2016	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	7.70
CY2017Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.16
CY2017Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.34
CY2017Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.32
CY2017Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.50
CY2017	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	10.34
CY2018Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	4.16
CY2018Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	4.82
CY2018Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	5.17
CY2018Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	7.15
CY2018	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	21.29
CY2016	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.327
CY2017	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.423
CY2018	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.043
CY2016	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.000
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.157
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.027
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Deductions Medicare Prescription Drug Benefit EffectiveIncomeTaxRateReconciliationDeductionsMedicarePrescriptionDrugBenefit	0.019
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Deductions Medicare Prescription Drug Benefit EffectiveIncomeTaxRateReconciliationDeductionsMedicarePrescriptionDrugBenefit	0.017
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Deductions Medicare Prescription Drug Benefit EffectiveIncomeTaxRateReconciliationDeductionsMedicarePrescriptionDrugBenefit	0.006
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Deductions Qualified Production Activities EffectiveIncomeTaxRateReconciliationDeductionsQualifiedProductionActivities	0.028
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Deductions Qualified Production Activities EffectiveIncomeTaxRateReconciliationDeductionsQualifiedProductionActivities	0.026
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Deductions Qualified Production Activities EffectiveIncomeTaxRateReconciliationDeductionsQualifiedProductionActivities	0.000
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.088
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.007
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.019
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.006
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.020
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.004
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.109
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.090
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.025
CY2016	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.013
CY2017	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.001
CY2018	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.001
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.012
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.013
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.026
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	191800000	USD
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	261800000	USD
CY2016	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-22600000	USD
CY2017	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	14700000	USD
CY2018	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-41900000	USD
CY2017	us-gaap	Gain Loss On Interest Rate Cash Flow Hedge Ineffectiveness GainLossOnInterestRateCashFlowHedgeIneffectiveness	0	USD
CY2018	us-gaap	Gain Loss On Interest Rate Cash Flow Hedge Ineffectiveness GainLossOnInterestRateCashFlowHedgeIneffectiveness	0	USD
CY2017	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-30100000	USD
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	1329800000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	2078500000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	2553500000	USD
CY2016	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	434300000	USD
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	880000000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	109100000	USD
CY2016	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	481400000	USD
CY2017	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	754800000	USD
CY2018	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	205600000	USD
CY2016	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	254000000	USD
CY2017	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-23200000	USD
CY2018	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	210000000	USD
CY2016	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	143800000	USD
CY2017	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	362700000	USD
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	268900000	USD
CY2016	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	244300000	USD
CY2017	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-113100000	USD
CY2018	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-194500000	USD
CY2016	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	360100000	USD
CY2017	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-318800000	USD
CY2018	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	140000000	USD
CY2016	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	149800000	USD
CY2017	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	314200000	USD
CY2018	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	387900000	USD
CY2016	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-36100000	USD
CY2017	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	113300000	USD
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	55700000	USD
CY2016	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	900000	shares
CY2017	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2018	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2016	us-gaap	Interest Expense InterestExpense	7200000	USD
CY2017	us-gaap	Interest Expense InterestExpense	25100000	USD
CY2018	us-gaap	Interest Expense InterestExpense	28200000	USD
CY2016	us-gaap	Interest Expense Lessee Assets Under Capital Lease InterestExpenseLesseeAssetsUnderCapitalLease	5400000	USD
CY2017	us-gaap	Interest Expense Lessee Assets Under Capital Lease InterestExpenseLesseeAssetsUnderCapitalLease	19500000	USD
CY2018	us-gaap	Interest Expense Lessee Assets Under Capital Lease InterestExpenseLesseeAssetsUnderCapitalLease	21500000	USD
CY2016	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	400000	USD
CY2017	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	0	USD
CY2018	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	0	USD
CY2016	us-gaap	Interest Paid Net InterestPaidNet	5500000	USD
CY2017	us-gaap	Interest Paid Net InterestPaidNet	18700000	USD
CY2018	us-gaap	Interest Paid Net InterestPaidNet	22300000	USD
CY2017Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	21800000	USD
CY2018Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	24400000	USD
CY2017Q4	us-gaap	Inventory Net InventoryNet	726100000	USD
CY2018Q4	us-gaap	Inventory Net InventoryNet	1151200000	USD
CY2017Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	190000000	USD
CY2018Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	226800000	USD
CY2017Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	302000000	USD
CY2018Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	571100000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	2620200000	USD
CY2018Q4	us-gaap	Liabilities Liabilities	2977200000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8764300000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11734500000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1135500000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1442800000	USD
CY2018Q4	us-gaap	Line Of Credit LineOfCredit	0	USD
CY2017Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	596800000	USD
CY2018Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	1342200000	USD
CY2017Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	1486500000	USD
CY2018Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	1755000000	USD
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1046800000	USD
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1005200000	USD
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1463000000	USD
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-24400000	USD
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-77100000	USD
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-700500000	USD
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1485900000	USD
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1307100000	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	2195100000	USD
CY2016	us-gaap	Net Income Loss NetIncomeLoss	895500000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	248900000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	387700000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	388300000	USD
CY2017Q4	us-gaap	Net Income Loss NetIncomeLoss	173500000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	1198500000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	478000000	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	551400000	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	594700000	USD
CY2018Q4	us-gaap	Net Income Loss NetIncomeLoss	820400000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	2444400000	USD
CY2016	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	895900000	USD
CY2017	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	1198500000	USD
CY2018	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	2444400000	USD
CY2016	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-900000	USD
CY2017	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1100000	USD
CY2018	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	19100000	USD
CY2018	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	1330700000	USD
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	2079600000	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	2534400000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	25400000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	10400000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	1500000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	2200000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	3400000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	3800000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	4100000	USD
CY2016	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	16800000	USD
CY2017	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	4300000	USD
CY2018	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	4900000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	129800000	USD
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	164600000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	77900000	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	127400000	USD
CY2016	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-21400000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	13400000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-6300000	USD
CY2016	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	0	USD
CY2017	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	800000	USD
CY2018	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	700000	USD
CY2016	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-21400000	USD
CY2016	us-gaap	Proceeds From Repayments Of Long Term Debt And Capital Securities ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities	5100000	USD
CY2017	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	12700000	USD
CY2018	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-7000000	USD
CY2017Q4	us-gaap	Other Inventory Net Of Reserves OtherInventoryNetOfReserves	212300000	USD
CY2018Q4	us-gaap	Other Inventory Net Of Reserves OtherInventoryNetOfReserves	328900000	USD
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	152000000	USD
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	361700000	USD
CY2016	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-45100000	USD
CY2017	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-63500000	USD
CY2018	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-12100000	USD
CY2016	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	6300000	USD
CY2017	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	24000000	USD
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	47300000	USD
CY2016	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	0	USD
CY2017	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	0	USD
CY2018	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	10000000	USD
CY2016	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
CY2017	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
CY2018	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	4400000	USD
CY2016	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	643400000	USD
CY2017	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	0	USD
CY2018	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	0	USD
CY2016	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	143200000	USD
CY2017	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	301700000	USD
CY2018	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	187200000	USD
CY2016	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	809400000	USD
CY2017	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	1277200000	USD
CY2018	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	1845500000	USD
CY2016	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	511900000	USD
CY2017	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	272600000	USD
CY2018	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	383100000	USD
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	30000000	shares
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	30000000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	225100000	USD
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	243300000	USD
CY2016	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	126700000	USD
CY2017	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	240200000	USD
CY2018	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	114500000	USD
CY2017	us-gaap	Proceeds From Repayments Of Long Term Debt And Capital Securities ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities	57000000	USD
CY2018	us-gaap	Proceeds From Repayments Of Long Term Debt And Capital Securities ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities	0	USD
CY2016	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	274500000	USD
CY2017	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	544600000	USD
CY2018	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	775600000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2924900000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3304500000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2358600000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2575800000	USD
CY2016	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
CY2017	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
CY2018	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
CY2016	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	12900000	USD
CY2017	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	USD
CY2018	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	USD
CY2016	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	32800000	USD
CY2017	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	19900000	USD
CY2018	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	0	USD
CY2016	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2052300000	USD
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2075100000	USD
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2186100000	USD
CY2016Q4	us-gaap	Restricted Cash RestrictedCash	12500000	USD
CY2017Q4	us-gaap	Restricted Cash RestrictedCash	12500000	USD
CY2018Q4	us-gaap	Restricted Cash RestrictedCash	12500000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	2946700000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	5254300000	USD
CY2016	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4860400000	USD
CY2017Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1319000000	USD
CY2017Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1470100000	USD
CY2017Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1500700000	USD
CY2017Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1582400000	USD
CY2017	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5872200000	USD
CY2018Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1511500000	USD
CY2018Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1608000000	USD
CY2018Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1663500000	USD
CY2018Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1927800000	USD
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6710800000	USD
CY2017Q4	us-gaap	Securities Owned Not Readily Marketable SecuritiesOwnedNotReadilyMarketable	37500000	USD
CY2018Q4	us-gaap	Securities Owned Not Readily Marketable SecuritiesOwnedNotReadilyMarketable	45500000	USD
CY2016	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1177700000	USD
CY2017	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1320400000	USD
CY2018	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1556200000	USD
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	559900000	USD
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	507300000	USD
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	427400000	USD
CY2016	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	48000000	USD
CY2016	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	16600000	USD
CY2017	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	19400000	USD
CY2018	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	26900000	USD
CY2017	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2018	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2016	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	115200000	USD
CY2017	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	240600000	USD
CY2018	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	114200000	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	3654800000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	4449300000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	6144100000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	8757300000	USD
CY2017Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	200000	USD
CY2018Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	20800000	USD
CY2017Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	3763868	shares
CY2018Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	3990021	shares
CY2017Q4	us-gaap	Treasury Stock Value TreasuryStockValue	316200000	USD
CY2018Q4	us-gaap	Treasury Stock Value TreasuryStockValue	396400000	USD
CY2016	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	0	USD
CY2018	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	80200000	USD
CY2015Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	116600000	USD
CY2016Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	117200000	USD
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	146200000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	189500000	USD
CY2016	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	45600000	USD
CY2017	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	49000000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	51400000	USD
CY2016	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	-42300000	USD
CY2017	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	-5600000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	5600000	USD
CY2016Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	107200000	USD
CY2017Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	146200000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	189500000	USD
CY2015Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	55300000	USD
CY2016Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	45800000	USD
CY2017Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	85300000	USD
CY2018Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	91400000	USD
CY2016	us-gaap	Valuation Allowances And Reserves Charged To Other Accounts ValuationAllowancesAndReservesChargedToOtherAccounts	278200000	USD
CY2017	us-gaap	Valuation Allowances And Reserves Charged To Other Accounts ValuationAllowancesAndReservesChargedToOtherAccounts	408300000	USD
CY2018	us-gaap	Valuation Allowances And Reserves Charged To Other Accounts ValuationAllowancesAndReservesChargedToOtherAccounts	478900000	USD
CY2016	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	287700000	USD
CY2017	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	368800000	USD
CY2018	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	472800000	USD
CY2016Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	0	USD
CY2016	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	11600000	shares
CY2017	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	9600000	shares
CY2018	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	6900000	shares
CY2016	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	116300000	shares
CY2017	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	115900000	shares
CY2018	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	114800000	shares
CY2016	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	104700000	shares
CY2017	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	106300000	shares
CY2018	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	107900000	shares
CY2018	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Credit Risk</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments which potentially expose the Company to concentrations of credit risk consist of cash, cash equivalents, certain financial instruments, and accounts receivable. In accordance with the Company's policies, the Company mandates asset diversification and monitors exposure with its counterparties. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Concentrations of credit risk with respect to accounts receivable are significant. The Company has a concentration of credit risk associated with the receivables due from its collaborators Bayer, Sanofi, and Teva. The Company is also subject to credit risk with accounts receivable from its product sales, which are due from several distributors and specialty pharmacies (the Company's customers). As of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and 2017, three individual customers accounted for </font><font style="font-family:inherit;font-size:10pt;">99%</font><font style="font-family:inherit;font-size:10pt;"> of the Company's net trade accounts receivable balances. The Company has contractual payment terms with each of its customers, and the Company monitors its customers' financial performance and credit worthiness so that it can properly assess and respond to any changes in their credit profile. </font></div></div>
CY2018	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. </font></div></div>

Files In Submission

Name	View Source	Status
R52.htm	Edgar Link	pending
0001532176-19-000009-index-headers.html	Edgar Link	pending
0001532176-19-000009-index.html	Edgar Link	pending
0001532176-19-000009.txt	Edgar Link	pending
0001532176-19-000009-xbrl.zip	Edgar Link	pending
chart-6f8415e8bd085de9b0e.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
regn-123118x10k.htm	Edgar Link	pending
regn-20181231.xml	Edgar Link	completed
regn-20181231.xsd	Edgar Link	pending
regn-20181231_cal.xml	Edgar Link	unprocessable
regn-20181231_def.xml	Edgar Link	unprocessable
regn-20181231_lab.xml	Edgar Link	unprocessable
regn-20181231_pre.xml	Edgar Link	unprocessable
regn-ex_1017xamendedio.htm	Edgar Link	pending
regn-ex_10217xstockoptiona.htm	Edgar Link	pending
regn-ex_10218xstockoptiona.htm	Edgar Link	pending
regn-ex_10219xar2014ltiprs.htm	Edgar Link	pending
regn-ex_10220xar2014ltipnq.htm	Edgar Link	pending
regn-ex_10221xar2014ltiprs.htm	Edgar Link	pending
regn-ex_211x12312018x10k.htm	Edgar Link	pending
regn-ex_231x12312018x10k.htm	Edgar Link	pending
regn-ex_311x12312018x10k.htm	Edgar Link	pending
regn-ex_312x12312018x10k.htm	Edgar Link	pending
regn-ex_32x12312018x10k.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$REGN
REGENERON PHARMACEUTICALS, INC. Stock $regn

2017 Q4 Form 10-K Financial Statement

#000153217619000009 Filed on February 07, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$REGN REGENERON PHARMACEUTICALS, INC. Stock $regn

2017 Q4 Form 10-K Financial Statement

#000153217619000009 Filed on February 07, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$REGN
REGENERON PHARMACEUTICALS, INC. Stock $regn